A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-07-23
Adverse events
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 121); relationship: N
Grade 2 Anaemia — outcome: UNKNOWN; onset 2023-05-23 (study day 291); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-15 (study day 344); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-17 (study day 499); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 509); relationship: not assessed
Data queries
No data queries.